Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

about

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials

P2860

Q57495648-ACD9A2AD-00E6-4E41-A35B-6F5F9FBE2C7E

P2860

Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

Item

http://www.wikidata.org/entity/Q39088664

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@en

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@nl

type

Item

label

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@en

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@nl

prefLabel

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@en

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@nl

P1476

Brief Report: Longitudinal Pat ...... ons for Clinical Trial Design.

@en

P2093

Anita Roach

http://www.w3.org/2001/XMLSchema#string

Bevra Hahn

http://www.w3.org/2001/XMLSchema#string

Joan Merrill

http://www.w3.org/2001/XMLSchema#string

Kenneth Kalunian

http://www.w3.org/2001/XMLSchema#string

Lupus Foundation of America Collective Data Analysis Initiative Group

http://www.w3.org/2001/XMLSchema#string

Mimi Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).

P304

785-790

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.40013

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Izmirly

P577

2016-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27992696

http://www.w3.org/2001/XMLSchema#string

Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

about

P2860

P2860

Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698